Go back

AI vital for drug discovery, companies say

Artificial intelligence is becoming increasingly important for small and medium-sized pharmaceutical businesses, but there is a need for better curated large-scale data, a study on the state of drug discovery in the UK has revealed.

Ninety per cent of the 60 drug-discovery SMEs that replied to a survey said they were using or needed data science, with half of them specifically needing AI and machine learning. Problems around accessing data were also flagged by these companies, according to a report published by the Medicines Discovery Catapult and the trade group the BioIndustry Association on 13 May.

“The field is still being held back by the availability of well-curated, large-scale data, and models to make pharma data available,” said the two organisations.

This article on Research Professional News is only available to Research Professional or Pivot-RP users.

Research Professional users can log in and view the article via this link

Pivot-RP users can log in and view the article via this link.